Cell Therapeutics Announces Results from Preclinical Study of Pixantrone at AACR-NCI-EORTC Conference

Cell Therapeutics CTIC today announced the presentation of findings from a preclinical study of PIXUVRI that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.  PIXUVRI is a first-in-class aza-anthracenedione with unique structural and physiochemical properties that is currently approved in the European Union for use as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.  The study results were presented by Neil Beeharry, Ph.D., at the Fox Chase Cancer Center during a poster session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held October 19-23, 2013 in Boston, MA.  "The study results suggest that PIXUVRI is unique in its mechanism for inducing tumor cell death, thereby supporting the thesis that it is the first approved drug in a new class of anti-cancer agents.  PIXUVRI's mechanism of action is differentiated from the cytotoxic action induced by anthracyclines and could be the basis for the efficacy and safety profile of the drug," stated Dr. See full press release